0000950170-25-015693.txt : 20250206 0000950170-25-015693.hdr.sgml : 20250206 20250206200843 ACCESSION NUMBER: 0000950170-25-015693 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250204 FILED AS OF DATE: 20250206 DATE AS OF CHANGE: 20250206 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Crystal Adam CENTRAL INDEX KEY: 0001825445 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39485 FILM NUMBER: 25598880 MAIL ADDRESS: STREET 1: C4 THERAPEUTICS, INC. STREET 2: 490 ARSENAL WAY, SUITE 200 CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Tango Therapeutics, Inc. CENTRAL INDEX KEY: 0001819133 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 901 CITY: BOSTON STATE: MA ZIP: 02215 BUSINESS PHONE: (857) 320-4900 MAIL ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 901 CITY: BOSTON STATE: MA ZIP: 02215 FORMER COMPANY: FORMER CONFORMED NAME: BCTG Acquisition Corp. DATE OF NAME CHANGE: 20200723 4 1 ownership.xml 4 X0508 4 2025-02-04 0001819133 Tango Therapeutics, Inc. TNGX 0001825445 Crystal Adam C/O TANGO THERAPEUTICS, INC., 201 BROOKLINE AVE., SUITE 901 BOSTON MA 02215 false true false false See Remarks false Common Stock 2025-02-04 4 S false 7432 2.988 D 165061 D Common Stock 2025-02-05 4 S false 6851 3.1614 D 158210 D The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Represents the weighted average sales price per share. The shares sold at prices ranging from $2.86 to $3.07 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Represents the weighted average sales price per share. The shares sold at prices ranging from $3.00 to $3.245 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. President, Research & Development /s/ Douglas Barry, attorney-in-fact 2025-02-06